Newtechco announced the signing of multiple partnerships aimed at bolstering its position in the pharmaceutical, technology, and infrastructure sectors during its 10th anniversary ceremony held recently in Hanoi.
Partnerships poised to fuel growth
The first partnership was established with Lotus International Pte. Ltd., a global pharmaceutical company with a presence in Taiwan, Singapore, and Vietnam. This collaboration is expected to enhance Newtechco’s pharmaceutical offerings and market reach. Newtechco also partnered with the Korean Association of Science and Technology Business (KASTAB) to facilitate technology transfer and innovation in the healthcare sector.
In addition, the Vietnamese company joined forces with Keppel EaaS Vietnam, a subsidiary of the Singapore-based Keppel, to explore synergies in sustainable infrastructure and energy solutions. Newtechco also signed a partnership with VCCorp, a technology solutions provider, to leverage digital transformation and enhance operational efficiency.
At the same time, Newtechco entered into a tripartite partnership with Cermed GmbH and RadioVaxx GmbH, German companies specializing in nuclear medicine and radiopharmaceutical solutions. This partnership aims to advance cancer treatment and diagnosis in Vietnam.
Speaking at the event, Dr. Ralph Markus Wirtz, chief strategy officer of RadioVaxx GmbH, emphasized the importance of collaboration in sharing medical knowledge among countries. He said developing countries like Vietnam can benefit from advanced medical technologies by creating a platform for knowledge sharing.
With a decade of experience, Newtechco has established itself as a strategic partner, connecting Vietnamese businesses with global corporations. Leveraging its deep understanding of promising foreign investment inflows, the Hanoi-based business is committed to supporting the growth of Vietnam’s drug manufacturing industry and ensuring its long-term success.
First decade of expansion
Vo Thi Tuan Anh, chairwoman of Newtechco’s Board of Directors, said the 10-year journey has been marked by significant challenges and strategic growth. Beyond its core import-export and financial investment activities, the company has emerged as a key player in facilitating foreign direct investment into Vietnam.
By providing consulting services and fostering strategic partnerships, Newtechco has become an advisor to both domestic and international businesses. This is evidenced by the increasing number of investors seeking Newtechco’s expertise when entering the Vietnamese market.
A pivotal moment arrived in November 2022 when Newtechco facilitated a meeting between domestic biotech firms and the U.S.-based Biotechnology Innovation Organization (BIO). Building on this momentum, a memorandum of understanding (MOU) was signed in April 2023, solidifying a partnership between the Drug Administration of Vietnam under the Ministry of Health, Makara Capital Partners Pte., Ltd., Sakae Corporate Advisory Pte., Ltd., and Newtechco Group.
Since June, the consortium has invested in a pharmaceutical and biotech (bio-pharma) industrial park in the northern province of Thai Binh. Covering 330 hectares in Quynh Phu District, the bio-pharma industrial park aims to establish a leading center for pharmaceutical and biotechnology production in Vietnam.
In the eyes of investors, the park’s primary goals include diversifying product lines, enhancing production capabilities, cultivating a skilled workforce, and prioritizing environmental protection. Overall, it is expected to attract both domestic and foreign investors, thereby stimulating the growth of Vietnam’s pharmaceutical industry.
Newtechco’s efforts are closely aligned with Vietnam’s strategic vision for the pharmaceutical industry. This synergy is evident in the Government’s proactive measures to foster a conducive environment for pharmaceutical investment and innovation, as stipulated in Decision No. 376 of the prime minister in March 2021.
“The Covid-19 pandemic further underscored the critical need for domestic pharmaceutical production,” Chairwoman Vo Thi Tuan Anh told The Saigon Times in an exclusive interview.
“By partnering with global industry leaders, we aim to attract foreign investment, enhance local capabilities, and position Vietnam as a regional hub for pharmaceutical manufacturing,” she added.
